Hanmi Pharm. Co., Ltd. (128940.KS)
KRW 269500.0
(-1.46%)
KRW 269500.0
(-1.46%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 224.88 Billion KRW | 42.25% |
| 2022 | 158.09 Billion KRW | 26.05% |
| 2021 | 125.41 Billion KRW | 156.07% |
| 2020 | 48.97 Billion KRW | -52.85% |
| 2019 | 103.87 Billion KRW | 24.3% |
| 2018 | 83.57 Billion KRW | 1.72% |
| 2017 | 82.16 Billion KRW | 206.9% |
| 2016 | 26.77 Billion KRW | -87.36% |
| 2015 | 211.79 Billion KRW | 514.77% |
| 2014 | 34.45 Billion KRW | -44.34% |
| 2013 | 61.89 Billion KRW | 28.56% |
| 2012 | 48.14 Billion KRW | 112.3% |
| 2011 | 22.67 Billion KRW | 696.47% |
| 2010 | -3.8 Billion KRW | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 58.1 Billion KRW | -24.18% |
| 2024 Q3 | 50.97 Billion KRW | -12.28% |
| 2024 Q1 | 76.64 Billion KRW | 2.13% |
| 2023 Q2 | 33.15 Billion KRW | -44.67% |
| 2023 Q3 | 57.51 Billion KRW | 73.48% |
| 2023 Q4 | 75.04 Billion KRW | 30.47% |
| 2023 FY | 224.88 Billion KRW | 42.25% |
| 2023 Q1 | 59.91 Billion KRW | 54.25% |
| 2022 FY | 158.09 Billion KRW | 26.05% |
| 2022 Q4 | 38.84 Billion KRW | -17.0% |
| 2022 Q3 | 46.8 Billion KRW | 48.21% |
| 2022 Q1 | 40.86 Billion KRW | -4.36% |
| 2022 Q2 | 31.57 Billion KRW | -22.71% |
| 2021 Q2 | 15.86 Billion KRW | -47.04% |
| 2021 Q1 | 29.94 Billion KRW | -28.54% |
| 2021 Q4 | 42.72 Billion KRW | 15.84% |
| 2021 Q3 | 36.88 Billion KRW | 132.52% |
| 2021 FY | 125.41 Billion KRW | 156.07% |
| 2020 Q2 | 10.6 Billion KRW | -63.11% |
| 2020 Q3 | -32.28 Billion KRW | -404.45% |
| 2020 Q4 | 41.91 Billion KRW | 229.83% |
| 2020 FY | 48.97 Billion KRW | -52.85% |
| 2020 Q1 | 28.74 Billion KRW | -3.84% |
| 2019 Q2 | 23.1 Billion KRW | -10.9% |
| 2019 Q4 | 29.89 Billion KRW | 19.84% |
| 2019 FY | 103.87 Billion KRW | 24.3% |
| 2019 Q1 | 25.93 Billion KRW | 63.34% |
| 2019 Q3 | 24.94 Billion KRW | 7.93% |
| 2018 Q2 | 19.94 Billion KRW | -24.01% |
| 2018 FY | 83.57 Billion KRW | 1.72% |
| 2018 Q4 | 15.87 Billion KRW | -26.14% |
| 2018 Q3 | 21.49 Billion KRW | 7.77% |
| 2018 Q1 | 26.25 Billion KRW | 1758.7% |
| 2017 Q4 | 1.41 Billion KRW | -94.93% |
| 2017 FY | 82.16 Billion KRW | 206.9% |
| 2017 Q2 | 21.54 Billion KRW | -31.32% |
| 2017 Q1 | 31.36 Billion KRW | 296.6% |
| 2017 Q3 | 27.83 Billion KRW | 29.2% |
| 2016 FY | 26.77 Billion KRW | -87.36% |
| 2016 Q1 | 22.56 Billion KRW | -86.84% |
| 2016 Q2 | 6.39 Billion KRW | -71.66% |
| 2016 Q4 | -15.95 Billion KRW | -215.9% |
| 2016 Q3 | 13.76 Billion KRW | 115.23% |
| 2015 Q2 | 2.44 Billion KRW | 15.92% |
| 2015 FY | 211.79 Billion KRW | 514.77% |
| 2015 Q1 | 2.11 Billion KRW | -69.08% |
| 2015 Q4 | 171.52 Billion KRW | 380.24% |
| 2015 Q3 | 35.71 Billion KRW | 1359.27% |
| 2014 Q1 | 17.94 Billion KRW | 4.2% |
| 2014 Q4 | 6.82 Billion KRW | 454.96% |
| 2014 Q3 | 1.23 Billion KRW | -85.43% |
| 2014 FY | 34.45 Billion KRW | -44.34% |
| 2014 Q2 | 8.44 Billion KRW | -52.93% |
| 2013 Q4 | 17.22 Billion KRW | 13.07% |
| 2013 Q1 | 17.96 Billion KRW | 1.55% |
| 2013 Q3 | 15.23 Billion KRW | 32.79% |
| 2013 Q2 | 11.47 Billion KRW | -36.16% |
| 2013 FY | 61.89 Billion KRW | 28.56% |
| 2012 Q4 | 17.69 Billion KRW | -3.12% |
| 2012 FY | 48.14 Billion KRW | 112.3% |
| 2012 Q2 | 11.2 Billion KRW | 1045.27% |
| 2012 Q1 | 978.42 Million KRW | 0.0% |
| 2012 Q3 | 18.26 Billion KRW | 62.99% |
| 2011 Q3 | 3.35 Billion KRW | -6.11% |
| 2011 Q1 | 3.39 Billion KRW | 0.0% |
| 2011 FY | 22.67 Billion KRW | 696.47% |
| 2011 Q2 | 3.57 Billion KRW | 5.18% |
| 2011 Q4 | - KRW | -100.0% |
| 2010 FY | -3.8 Billion KRW | 0.0% |
| 2010 Q3 | -5.45 Billion KRW | 0.0% |
| 2010 Q4 | - KRW | 100.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 364.53 Million KRW | -61590.541% |
| Dong-A Socio Holdings Co., Ltd. | 76.88 Billion KRW | -192.508% |
| Ildong Holdings Co., Ltd. | -79.56 Billion KRW | 382.654% |
| HANDOK Inc. | 12.57 Billion KRW | -1687.804% |
| Kukje Pharma Co., Ltd. | -1.98 Billion KRW | 11405.619% |
| Yuhan Corporation | 74.56 Billion KRW | -201.606% |
| Dong-A ST Co., Ltd. | 11.17 Billion KRW | -1911.77% |
| SAMSUNG PHARM. Co., LTD. | -18.04 Billion KRW | 1346.416% |
| Hanall Biopharma Co.,Ltd | 3.05 Billion KRW | -7258.656% |
| Ilyang Pharmaceutical Co.,Ltd | 14.35 Billion KRW | -1467.096% |
| Dong Sung Bio Pharm.Co.,Ltd. | 596.4 Million KRW | -37606.885% |
| MYUNGMOON Pharm co.,Ltd | 963.76 Million KRW | -23233.991% |
| Hana Pharm Co., Ltd. | 27.03 Billion KRW | -731.938% |
| Yuyu Pharma, Inc. | 364.53 Million KRW | -61590.541% |
| Ilsung Pharmaceuticals Co., Ltd. | -7.75 Billion KRW | 2999.476% |
| REYON Pharmaceutical Co., Ltd. | 4.03 Billion KRW | -5475.249% |
| Aprogen pharmaceuticals,Inc. | -69.95 Billion KRW | 421.492% |
| JW Holdings Corporation | 143.66 Billion KRW | -56.534% |
| Ildong Pharmaceutical Co., Ltd. | -53.41 Billion KRW | 520.994% |
| Chong Kun Dang Pharmaceutical Corp. | 246.59 Billion KRW | 8.806% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | -124.204% |
| Shin Poong Pharm.Co.,Ltd. | -47.39 Billion KRW | 574.517% |
| Hyundai Pharmaceutical Co., Ltd. | 6.92 Billion KRW | -3146.531% |
| Samil Pharmaceutical Co.,Ltd | 6.47 Billion KRW | -3375.258% |
| Jeil Pharmaceutical Co.,Ltd | 8.73 Billion KRW | -2475.594% |
| Yuyu Pharma, Inc. | 364.53 Million KRW | -61590.541% |
| Kwang Dong Pharmaceutical Co., Ltd. | 48.76 Billion KRW | -361.135% |
| Daewoong pharmaceutical Co.,Ltd | 133.4 Billion KRW | -68.571% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | -124.204% |
| Yuhan Corporation | 74.56 Billion KRW | -201.606% |
| Jeil Pharma Holdings Inc | 20.92 Billion KRW | -974.966% |
| Yungjin Pharm. Co., Ltd. | 3.11 Billion KRW | -7113.874% |
| Suheung Co., Ltd. | 42.99 Billion KRW | -423.049% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | -124.204% |
| Samjin Pharmaceuticals Co., Ltd. | 20.48 Billion KRW | -997.837% |
| Korea United Pharm Inc. | 54.94 Billion KRW | -309.256% |
| CKD Bio Corp. | -20.15 Billion KRW | 1215.915% |
| Daewon Pharmaceutical Co., Ltd. | 32.23 Billion KRW | -597.69% |
| Dongwha Pharm.Co.,Ltd | 25.3 Billion KRW | -788.8% |
| Whan In Pharm Co.,Ltd. | 32.52 Billion KRW | -591.42% |
| Shin Poong Pharm.Co.,Ltd. | -47.39 Billion KRW | 574.517% |
| Chong Kun Dang Holdings Corp. | 33.14 Billion KRW | -578.45% |
| Boryung Corporation | 68.26 Billion KRW | -229.42% |
| Bukwang Pharmaceutical Co., Ltd. | -37.49 Billion KRW | 699.745% |
| Ilyang Pharmaceutical Co.,Ltd | 14.35 Billion KRW | -1467.096% |
| JW Lifescience Corporation | 32.09 Billion KRW | -600.762% |